The new leukemia drug ‘Xospata’ has crossed the final barrier to reimbursement in Korea.

According to industry sources, Astellas Pharma Korea completed drug pricing negotiations for its acute myeloid leukemia (AML) treatment Xospata (gilteritinib) with the National Health Insurance Service.

Accordingly, if the agenda passes the Health Insurance Policy Deliberative Committee meeting in February, Xospata may be reimbursed from the following month (March).

Astellas has opted for the pharmacoeconomic evaluation exemption track to receive reimbursement for Xospata and therefore will be reimbursed under the Expenditure cap type of the Risk Sharing Agreement (RSA).